Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.

Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN.

Cell. 2018 Nov 15;175(5):1443. doi: 10.1016/j.cell.2018.11.003. No abstract available.

2.

High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.

Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN.

Cell. 2018 Nov 1;175(4):1014-1030.e19. doi: 10.1016/j.cell.2018.09.030. Epub 2018 Oct 18. Erratum in: Cell. 2018 Nov 15;175(5):1443.

PMID:
30343900
3.

Author Correction: Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW.

Nat Commun. 2018 Jul 26;9(1):3000. doi: 10.1038/s41467-018-05468-y.

4.

The RNA-Binding Protein HuR Posttranscriptionally Regulates IL-2 Homeostasis and CD4+ Th2 Differentiation.

Techasintana P, Ellis JS, Glascock J, Gubin MM, Ridenhour SE, Magee JD, Hart ML, Yao P, Zhou H, Whitney MS, Franklin CL, Martindale JL, Gorospe M, Davis WJ, Fox PL, Li X, Atasoy U.

Immunohorizons. 2017 Aug 1;1(6):109-123. doi: 10.4049/immunohorizons.1700017.

5.

Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW.

Nat Commun. 2017 Sep 15;8(1):562. doi: 10.1038/s41467-017-00627-z. Erratum in: Nat Commun. 2018 Jul 26;9(1):3000.

6.

Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology Keystone Symposia Meeting Summary.

Gubin MM.

Cancer Immunol Res. 2017 Jun;5(6):434-438. doi: 10.1158/2326-6066.CIR-17-0224.

7.

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.

Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD.

Cancer Immunol Res. 2017 Feb;5(2):106-117. doi: 10.1158/2326-6066.CIR-16-0391. Epub 2017 Jan 10.

8.

The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.

Ward JP, Gubin MM, Schreiber RD.

Adv Immunol. 2016;130:25-74. doi: 10.1016/bs.ai.2016.01.001. Epub 2016 Feb 10. Review.

9.

CANCER. The odds of immunotherapy success.

Gubin MM, Schreiber RD.

Science. 2015 Oct 9;350(6257):158-9. doi: 10.1126/science.aad4140. No abstract available.

PMID:
26450194
10.

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL.

Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27.

11.

Tumor neoantigens: building a framework for personalized cancer immunotherapy.

Gubin MM, Artyomov MN, Mardis ER, Schreiber RD.

J Clin Invest. 2015 Sep;125(9):3413-21. doi: 10.1172/JCI80008. Epub 2015 Aug 10. Review.

12.

Transcriptomic-Wide Discovery of Direct and Indirect HuR RNA Targets in Activated CD4+ T Cells.

Techasintana P, Davis JW, Gubin MM, Magee JD, Atasoy U.

PLoS One. 2015 Jul 10;10(7):e0129321. doi: 10.1371/journal.pone.0129321. eCollection 2015.

13.

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.

14.

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ.

Curr Opin Immunol. 2014 Apr;27:16-25. doi: 10.1016/j.coi.2014.01.004. Epub 2014 Feb 14. Review.

15.

Conditional knockout of the RNA-binding protein HuR in CD4⁺ T cells reveals a gene dosage effect on cytokine production.

Gubin MM, Techasintana P, Magee JD, Dahm GM, Calaluce R, Martindale JL, Whitney MS, Franklin CL, Besch-Williford C, Hollingsworth JW, Abdelmohsen K, Gorospe M, Atasoy U.

Mol Med. 2014 Mar 20;20:93-108. doi: 10.2119/molmed.2013.00127.

16.

Posttranscriptional gene regulation of IL-17 by the RNA-binding protein HuR is required for initiation of experimental autoimmune encephalomyelitis.

Chen J, Cascio J, Magee JD, Techasintana P, Gubin MM, Dahm GM, Calaluce R, Yu S, Atasoy U.

J Immunol. 2013 Dec 1;191(11):5441-50. doi: 10.4049/jimmunol.1301188. Epub 2013 Oct 28.

17.

Method for the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts using RIP-Chip.

Dahm GM, Gubin MM, Magee JD, Techasintana P, Calaluce R, Atasoy U.

J Vis Exp. 2012 Sep 29;(67). pii: 3851. doi: 10.3791/3851.

18.

Incisional hernia recurrence through genomic profiling: a pilot study.

Calaluce R, Davis JW, Bachman SL, Gubin MM, Brown JA, Magee JD, Loy TS, Ramshaw BJ, Atasoy U.

Hernia. 2013 Apr;17(2):193-202. doi: 10.1007/s10029-012-0923-4. Epub 2012 May 31.

19.

Coordinate regulation of GATA-3 and Th2 cytokine gene expression by the RNA-binding protein HuR.

Stellato C, Gubin MM, Magee JD, Fang X, Fan J, Tartar DM, Chen J, Dahm GM, Calaluce R, Mori F, Jackson GA, Casolaro V, Franklin CL, Atasoy U.

J Immunol. 2011 Jul 1;187(1):441-9. doi: 10.4049/jimmunol.1001881. Epub 2011 May 25.

20.

Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis.

Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP, Ma L, Brown A, Hoffman T, Rold TL, Atasoy U.

Cell Cycle. 2010 Aug 15;9(16):3337-46. doi: 10.4161/cc.9.16.12711. Epub 2010 Aug 17.

21.

The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer.

Calaluce R, Gubin MM, Davis JW, Magee JD, Chen J, Kuwano Y, Gorospe M, Atasoy U.

BMC Cancer. 2010 Apr 6;10:126. doi: 10.1186/1471-2407-10-126.

22.

[Injection solutions and modern technological problem of their production in pharmacy].

Umarov SZ, Bunin SA, Gubin MM, Gol'chenko AN.

Voen Med Zh. 2009 Feb;330(2):56-61. Russian. No abstract available.

PMID:
19351026

Supplemental Content

Loading ...
Support Center